Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has ...

Michelle Tarver, of the FDA's Center for Devices and Radiological Health, said: "Today's clearance is an important step for ...

The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The FDA cleared the first blood test on Friday to help diagnose Alzheimer's disease among older Americans already exhibiting ...

Experts say the test could dramatically improve access to earlier, more accurate diagnoses, particularly for older Americans ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...